FocalTherics (NASDAQ:FOCL) Receives $9.00 Consensus Target Price from Brokerages

FocalTherics (NASDAQ:FOCL) has been given an average rating of “Hold” by the five analysts that are currently covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, two have given a hold rating, one has given a buy rating and one has given a strong buy rating to the company. The average twelve-month price target among brokers that have covered the stock in the last year is $7.75.

Several equities research analysts have commented on FOCL shares. Mizuho set a $15.00 price target on shares of FocalTherics and gave the stock an “outperform” rating in a research report on Friday, July 17th. HC Wainwright reaffirmed a “buy” rating and issued a $10.00 price objective on shares of FocalTherics in a research note on Tuesday, June 2nd. Wall Street Zen downgraded shares of FocalTherics from a “hold” rating to a “sell” rating in a report on Saturday, August 15th. Weiss Ratings reissued a “sell (d-)” rating on shares of FocalTherics in a research note on Monday. Finally, Piper Sandler restated a “neutral” rating and set a $4.00 target price on shares of FocalTherics in a report on Friday, August 14th.

Insider Buying and Selling

In related news, Director Joshua Levine acquired 10,000 shares of FocalTherics stock in a transaction dated Friday, August 14th. The stock was acquired at an average cost of $4.75 per share, with a total value of $47,500.00. Following the purchase, the director directly owned 45,000 shares in the company, valued at $213,750. The trade was a 28.57% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Lance Willsey bought 50,000 shares of the firm’s stock in a transaction that occurred on Friday, August 14th. The stock was bought at an average price of $4.75 per share, for a total transaction of $237,500.00. Following the completion of the acquisition, the director directly owned 1,291,780 shares in the company, valued at approximately $6,135,955. The trade was a 4.03% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders have purchased 116,000 shares of company stock valued at $551,000 in the last three months. Insiders own 10.10% of the company’s stock.

Institutional Investors Weigh In On FocalTherics

Hedge funds have recently modified their holdings of the stock. Flax Pond Capital LLC purchased a new position in FocalTherics in the 4th quarter worth about $2,623,000. Rock Springs Capital Management LP lifted its stake in FocalTherics by 7.1% during the first quarter. Rock Springs Capital Management LP now owns 1,378,000 shares of the company’s stock valued at $5,126,000 after buying an additional 91,500 shares in the last quarter. Kovack Advisors Inc. purchased a new stake in FocalTherics during the fourth quarter valued at about $53,000. Leonteq Securities AG acquired a new position in shares of FocalTherics in the fourth quarter worth about $313,000. Finally, Lido Advisors LLC acquired a new position in shares of FocalTherics in the first quarter worth about $40,000. 62.74% of the stock is owned by hedge funds and other institutional investors.

FocalTherics Stock Performance

Shares of NASDAQ FOCL opened at $4.24 on Friday. The firm’s fifty day moving average price is $5.36. The company has a current ratio of 1.60, a quick ratio of 0.99 and a debt-to-equity ratio of 1.79. The company has a market cap of $158.92 million, a price-to-earnings ratio of -4.12 and a beta of -0.04. FocalTherics has a 1 year low of $1.30 and a 1 year high of $6.40.

FocalTherics (NASDAQ:FOCL) last posted its quarterly earnings data on Friday, August 14th. The company reported ($0.39) EPS for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.19). FocalTherics had a negative return on equity of 248.00% and a negative net margin of 56.26%.The firm had revenue of $13.20 million during the quarter. On average, research analysts predict that FocalTherics will post -0.78 earnings per share for the current fiscal year.

About FocalTherics

EDAP TMS SA, together with its subsidiaries, develops, produces, markets, distributes, and maintains a portfolio of minimally invasive medical devices for the treatment of urological diseases in Asia, France, the United States, and internationally. It operates in three segments: High Intensity Focused Ultrasound (HIFU), Extracorporeal ShockWave Lithotripsy (ESWL), and Distribution Services (DIST). The HIFU segment develops, manufactures, and markets medical devices based on HIFU technology for the minimally invasive treatment of urological and other clinical indications.